Boehringer Ingelheim Reports the Acquisition of Saiba Animal Health, Strengthening its R&D Portfolio Focusing on Animal Health
Shots:
- Boehringer Ingelheim has acquired Saiba Animal Health, adding technology platform to strengthen its pet therapeutics R&D pipeline. Details of the agreement were undisclosed
- By utilizing novel therapeutic vaccine approach, Saiba’s technology platform produces an immune response against chronic diseases like allergy, inflammation & pain
- Saiba’s vaccines use virus-like particles to trigger the animal's immune system by producing neutralizing antibodies against disease-causing proteins. This approach may offer long-lasting effects & better treatment outcomes with greater convenience for pet owners
Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim & Saiba Animal Health
Related News:- Boehringer Ingelheim Reports the Acquisition of Nerio Therapeutics for $1.3B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
